Tetracyclines, sulfonamides, and metronidazole;Tetraciclinas, sulfamidas y metronidazol

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 2, 2010, Pages 122-130

  Vicente, Diego ^a,b   Pérez Trallero, Emilio ^a,b,c  

^a HOSPITAL DONOSTIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Co trimoxazole; Sulfadiazine; Tigecycline

Indexed keywords

DOXYCYCLINE; METRONIDAZOLE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TIGECYCLINE;

ANAEROBIC BACTERIUM; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; DRUG RESISTANCE; HUMAN; INFECTION; NONHUMAN; PARASITOSIS; PROTOZOON;

ANTI-BACTERIAL AGENTS; ANTIPARASITIC AGENTS; BACTERIAL INFECTIONS; DNA DAMAGE; DRUG RESISTANCE, BACTERIAL; FOLIC ACID ANTAGONISTS; HUMANS; METRONIDAZOLE; MOLECULAR STRUCTURE; PARASITIC DISEASES; PROTEIN SYNTHESIS INHIBITORS; SULFONAMIDES; TETRACYCLINES;

EID: 74649085949     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.10.002     Document Type: Article

References (40)

1. Klein N.C., and Cunha B.A. Tetracyclines. Med Clin North Am 79 (1995) 789-801
2. Joshi N., and Miller D.Q. Doxycycline revisited. Arch Intern Med 157 (1997) 1421-1428
3. Smilack J.D. The tetracyclines. Mayo Clin Proc 74 (1999) 727-729
4. Chopra I., and Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65 (2001) 232-260
5. Chopra I. Tetracyclines. In: Finch R.G., Greenwood D., Norrby S.R., and Whitley R.J. (Eds). Antibiotic and chemotherapy. 8 ed (2003), Churchill Livingstone, Philadelphia 393-406
6. Agencia Española de Medicamentos y Productos sanitarios (AEMPS) y Dirección General de Farmacia y Productos Sanitarios (DGFPS). Uso de antibióticos en España [consultado 7/1/2010]. Disponible en: http://www.agemed.es/profHumana/observatorio/docs/Evo_uso_antibioticos96-06.pdf.
7. OMS. Medicamentos Esenciales 15 ed. Lista Modelo de la OMS. Marzo 2007 [consultado 7/1/2010]. Disponible en: http://www.who.int/medicines/publications/08_SPANISH_FINAL_EML15.pdf.
8. MacGowan A.P. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 62 (2008) i11-i16
9. Pillar C.M., Draghi D.C., Dowzicky M.J., and Sahm D.F. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol 46 (2008) 2862-2867
10. Betriu C., Rodríguez-Avial I., Gómez M., Culebras E., López F., Álvarez J., et al. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis 56 (2006) 437-444
11. Nørskov-Lauritsen N., Marchandin H., and Dowzicky M.J. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 34 (2009) 121-130
12. Anthony K.B., Fishman N.O., Linkin D.R., Gasink L.B., Edelstein P.H., and Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 46 (2008) 567-570
13. Daurel C., Fiant A.L., Brémont S., Courvalin P., and Leclercq R. Emergence of an enterobacter hormaechei with reduced susceptibility to tigecycline under tigecycline therapy. Antimicrob Agents Chemother (2009) [Epub ahead of print]
14. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., and Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: A review of the scientific evidence. J Antimicrob Chemother 62 (2008) 45-55
15. Reid G.E., Grim S.A., Aldeza C.A., Janda W.M., and Clark N.M. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27 (2007) 1198-1201
16. Akers K.S., Mende K., Yun H.C., Hospenthal D.R., Beckius M.L., Yu X., et al. Tetracycline susceptibility testing and resistance genes in isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex from a US military hospital. Antimicrob Agents Chemother 53 (2009) 2693-2695
17. Fernández-Roblas R., Martín-de-Hijas N.Z., Fernández-Martínez A.I., García-Almeida D., Gadea I., and Esteban J. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob Agents Chemother 52 (2008) 4184-4186
18. Purdy S., and De Berker D. Acne. BMJ 333 (2006) 949-953
19. Bell D.M., Kozarsky P.E., and Stephens D.S. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis 8 (2002) 222-225
20. Kim H.S., and Suh Y.H. Minocycline and neurodegenerative diseases. Behav Brain Res 196 (2009) 168-179
21. Guirao X., Arias J., Badía J.M., García-Rodríguez J.A., Mensa J., Álvarez-Lerma F., et al. Recomendaciones en el tratamiento empírico de la infección intraabdominal. Rev Esp Qumiot 22 (2009) 151-172
22. Skold O. Sulfonamide resistance: Mechanisms and trends. Drug Resist Updat 3 (2000) 155-160
23. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 32 (2001) 1608-1614
24. Greenwood D. Sulphonamides. In: Finch R.G., Greenwood D., Norrby S.R., and Whitley R.J. (Eds). Antibiotic and chemotherapy. 8 ed (2003), Churchill Livingstone, Philadelphia 385-392
25. Masters P.A., O'Bryan T.A., Zurlo J., Miller D.Q., and Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 163 (2003) 402-410
26. Kärpänoja P., Nyberg S.T., Bergman M., Voipio T., Paakkari P., Huovinen P., et al., Finnish Study Group for Antimicrobial Resistance (FiRe Network). Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 52 (2008) 2480-2485
27. Huang L., Crothers K., Atzori C., Benfield T., Miller R., Rabodonirina M., et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis 10 (2004) 1721-1728
28. Iliades P., Meshnick S.R., and Macreadie I.G. Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs. Antimicrob Agents Chemother 49 (2005) 741-748
29. Freeman C.D., Klutman N.E., and Lamp K.C. Metronidazole. A therapeutic review and update. Drugs 54 (1997) 679-708
30. Martínez V., and Caumes E. Metronidazole. Ann Dermatol Venereol 128 (2001) 903-909
31. Edwards D. Nitroimidazoles. In: Finch R.G., Greenwood D., Norrby S.R., and Whitley R.J. (Eds). Antibiotic and chemotherapy. 8 ed (2003), Churchill Livingstone, Philadelphia 385-392
32. Raether W., and Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 90 (2003) 19-39
33. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 43 (1999) 1533-1541
34. Land K.M., and Johnson P.J. Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa. Drug Resist Updat 2 (1999) 289-294
35. Upcroft P., and Upcroft J.A. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 14 (2001) 150-164
36. Patel E.H., Paul L.V., Casanueva A.I., Patrick S., and Abratt V.R. Overexpression of the rhamnose catabolism regulatory protein, RhaR: A novel mechanism for metronidazole resistance in Bacteroides thetaiotaomicron. J Antimicrob Chemother 64 (2009) 267-273
37. Hedberg M., Nord C.E., and The ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 9 (2003) 475-488
38. Brazier J., Chmelar D., Dubreuil L., Feierl G., Hedberg M., Kalenic S., et al., ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. European surveillance study on antimicrobial susceptibility of Gram-positive anaerobic cocci. Int J Antimicrob Agents 31 (2008) 316-320
39. Bauer M.P., Van Dissel J.T., and Kuijper E.J. Clostridium difficile: Controversies and approaches to management. Curr Opin Infect Dis (2009) [Epub ahead of print]
40. Centers for Disease Control and Prevention, Workowski K.A., and Berman S.M. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55 (2006) 1-94